TB-500 Dosage: How It's Used

If you came here for a number, the honest answer is the most useful thing this page can give you: there isn’t a trustworthy one, and the reason why matters more than any figure you’ll find elsewhere.

TB-500 is unusual even among unapproved peptides. Most “dosage guides” for a research compound at least extrapolate from a real human study of the actual substance. With TB-500, that study doesn’t exist. There is no completed human efficacy trial and no published human pharmacokinetic data for the injected fragment that vendors sell as “TB-500.” On top of that, the word “TB-500” doesn’t reliably name one molecule. So before you can sensibly ask “how much,” you run into two missing foundations that no amount of precision can paper over: you don’t know exactly what’s in the vial, and no human has ever been dosed on it in a controlled study. This page walks through how dosing is genuinely decided, what the popular protocols actually are, and why a fixed internet number is the part of this compound you should trust least.

How a TB-500 dose is actually decided

In a legitimate setting, a dose is never a figure lifted from a website. It’s an individualized decision a licensed prescriber makes for a specific person, based on the goal, the clinical picture, age and body size, the response over time, and what monitoring shows. It gets set conservatively and adjusted, not fixed in advance from a chart.

That framing matters even more for TB-500 than for better-studied peptides, because the inputs a prescriber would normally lean on — an approved label, established human pharmacokinetics, a dose-response curve — simply aren’t there for this molecule. A responsible provider treating anything in this space is reasoning from sparse data, individual response, and caution. None of that survives the journey to a one-size-fits-all “protocol” pasted under a buy button.

The problem underneath the number: you don’t know what’s in the vial

Every dose is a dose of something. With TB-500, you frequently don’t know what that something is.

“TB-500” is widely used as a loose label rather than a precise chemical identity. The product most vendors describe is a short synthetic fragment built around the actin-binding region of thymosin beta-4 — commonly the acetylated 17–23 fragment (Ac-LKKTETQ). But the same name gets attached to full-length 43–amino-acid thymosin beta-4, which is a different and much larger molecule, and sometimes to other fragments entirely, including ones marketed as “TB4 Frag” that center on a different active motif. Independent testing of gray-market vials has repeatedly found that what’s inside doesn’t always match the label, in identity as well as in purity.

This wrecks the entire premise of a milligram dose. A “2 mg” of one molecule is not pharmacologically equivalent to “2 mg” of a different one, and neither tells you anything if the vial actually contains 60% of what it claims, or a contaminant. A precise number applied to an undefined substance is precise only in appearance. This is why even sources that publish protocols quietly add a “get a certificate of analysis with mass-spec identity confirmation” caveat — they’re acknowledging that the dose is meaningless without first answering a question the buyer usually can’t.

Note: A milligram figure assumes a standardized product. For TB-500 that standard doesn’t reliably exist, so the dose inherits all the uncertainty of the vial it’s drawn from.

Why the “loading phase / maintenance” protocol isn’t what it looks like

Almost every TB-500 guide online follows the same shape: a “loading phase” of more frequent dosing for the first several weeks, then a “maintenance phase” of less frequent dosing afterward, often run in cycles. It looks clinical. The language — loading dose, building tissue levels, steady-state, saturation — is borrowed straight from real pharmacology.

The borrowing is the problem. A genuine loading dose is calculated from a drug’s measured human pharmacokinetics: its volume of distribution, its clearance, its half-life. For the injected TB-500 fragment, those human values haven’t been published. The “systemic saturation” story used to justify front-loading is a model extrapolated from animal experiments and mechanism, not something measured in people taking this fragment. So the two-phase calendar isn’t derived from how TB-500 behaves in a human body — it’s a convention that propagated across vendor pages until it started to look like a standard. Repetition isn’t evidence.

That’s the distinction worth carrying away: the dosing calendar you see is real in the sense that lots of people follow it, and unfounded in the sense that nothing measured in humans supports the specific structure. We describe its shape here precisely so you can recognize it for what it is — not reproduce it.

There is no human dose for the fragment — only borrowed credibility

When a TB-500 protocol gestures at “human safety data,” it is almost always reaching for studies of a different molecule.

The human research that exists belongs to full-length thymosin beta-4, not the TB-500 fragment, and it was given by routes that have nothing to do with a subcutaneous injection of the fragment. Early-phase trials of recombinant or synthetic full-length thymosin beta-4 were administered intravenously — for instance, safety studies in healthy volunteers and small cardiac and wound-healing programs. Those tell you something about a related parent protein delivered into a vein in a monitored clinical setting. They tell you essentially nothing reliable about how much of a short fragment to inject under the skin at home, because the molecule, the route, and the context are all different.

You may also encounter what looks like a current trial of the fragment itself in cardiovascular disease. Be careful: the most prominent such record circulating online is explicitly labeled as a fictional, illustrative example of a trial registry entry, not a real study, and it deliberately withholds dose levels. It is not evidence that a human dose has been established.

So TB-500 sits a step behind even other unapproved peptides on this axis. Some compounds at least have a real, if tiny, human dosing study of the actual substance to anchor a discussion. TB-500’s fragment has none — every number you find has been reverse-engineered from animal work and dressed in the credibility of trials that studied something else.

Why a fixed internet dose is unsafe even if the number were “right”

Set aside the identity and evidence problems for a moment and imagine the popular number were somehow exactly correct for some idealized person. It would still be unsafe to copy, for reasons specific to how this compound is actually obtained and used:

• Unknown concentration and purity. Gray-market vials vary in how much active compound they actually contain. The “right” dose of an under-dosed, over-dosed, or contaminated product is still the wrong dose. You’d be measuring against a number while drawing from an unknown.
• No monitoring loop. A real dose is the start of a feedback process — you watch for adverse effects and response and adjust. “Inject this schedule” with no evaluation removes the part that makes a dose safe.
• No individualization. Body size, the specific issue being targeted, other medications, and personal risk factors all move the right answer. A fixed figure ignores all of them by design.
• A theoretical-risk profile no one is watching. The proposed mechanism includes promoting new blood-vessel growth, which raises unresolved theoretical concerns — for example around any existing or suspected malignancy — that simply haven’t been characterized in humans. A self-set schedule has no one tracking for that.

The danger isn’t that the popular number is too high or too low. It’s that “buy this and follow this schedule” is self-administration of an unregulated injectable of uncertain identity, with the one element that would make a dose defensible — a clinician’s evaluation and ongoing monitoring — stripped out. For a fuller picture of what can go wrong, see TB-500 side effects and safety.

The stack problem: a “TB-500 dose” is usually two drugs

There’s one more reason a standalone TB-500 number is misleading: people rarely take TB-500 alone. It’s most often run in the so-called “Wolverine stack” alongside BPC-157, on the theory that one handles systemic healing and the other local repair. That combination has no direct human trial behind it either, but it dominates real-world use.

This means the dosing question people actually have isn’t “how much TB-500,” it’s “how much of a two-peptide program” — and once two unapproved compounds are co-administered, even the anecdotal dosing reports become impossible to interpret cleanly. A number presented as “the TB-500 dose” has usually been decontextualized from the stack it lived in. If your real interest is the combination, that’s its own subject; the honest version is at BPC-157 and TB-500 for healing, and the dosing logic for the partner compound is at BPC-157 dosage.

Monitoring, red flags, and what a legitimate route looks like

If a person pursues TB-500 through a clinician at all, the dose is only one part of a process. A legitimate provider establishes a baseline, sets a conservative starting point, watches for adverse effects and response, and adjusts — treating the number as provisional, not prescribed by the internet. The decision is theirs to own and revisit, not yours to copy.

The clearest warning sign runs in the opposite direction. “No evaluation, just buy and inject this schedule” is the red flag, not the convenience it’s marketed as. A dosing chart sitting next to an “add to cart” button, with no examination, no monitoring, and no acknowledgment that the vial’s contents are unverified, is the exact pattern this page exists to flag. The presence of a precise-looking protocol is not reassurance; for TB-500 specifically, it’s a sign the source is treating an undefined substance with no human dose data as if it were a standardized drug.

If you want the legitimate access routes laid out — telehealth evaluation, a clinic, and a prescription filled by a licensed pharmacy where that’s even available — that belongs on how to get TB-500 in the US, not here. This page is about why the number itself can’t be trusted in isolation.

Where TB-500 stands in 2026

A note on legal status, because it shapes whether any legitimate dosing conversation is even possible. TB-500 is not an FDA-approved drug for any indication, and despite what some product pages claim, it has not been “reclassified to Category 1.” The accurate 2026 picture is more unsettled: TB-500 was removed from the FDA’s 503A Category 2 list earlier in 2026, and it is on the advisory committee docket scheduled for July 23, 2026, which would weigh whether it belongs on the 503A bulk-substances list. Formal rulemaking is still pending. As of this writing, that means there is no clean, settled compounding route for it — a prescription might be written, but a licensed pharmacy may decline to fill it, and its thin history as a pharmacy-compounded product (versus a research chemical) means any legitimate supply would likely lag even a favorable decision.

Separately, and regardless of how that process resolves, TB-500 is prohibited at all times under the World Anti-Doping Agency’s peptide-hormone and growth-factor category. Real sanctions have followed: athletes have received multi-year bans for TB-500 use. If you’re subject to any testing, this isn’t a gray area.

All of this is current as of the date at the top of this page and may change; the moving parts live in the 2026 FDA peptide reclassification and are peptides legal in the US.

The bottom line is the one the whole page builds toward. A TB-500 “dosage” is a number resting on two voids — an undefined substance and a missing human study — usually pulled out of a two-drug stack and printed beside a product whose contents you can’t verify. The figure isn’t the useful part. Understanding why it can’t be trusted, and why dosing is a clinician’s individualized, monitored decision rather than a download, is.